文献速递外周动脉疾病

COMPASS与VOYAGER-PAD试验在法国症状性下肢动脉疾病患者中的外部适用性:COPART注册研究

Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2021-07-28

仅30.1%的患者符合低剂量利伐沙班联合阿司匹林方案,符合标准者缺血事件风险高于试验对照组,提示其绝对获益可能更大。

要点

  • 仅30.1%的症状性LEAD患者符合低剂量利伐沙班联合阿司匹林标准。
  • 不符合标准的主要原因为需抗凝、双联抗血小板、高出血风险、恶性肿瘤等。
  • 符合标准者的缺血事件风险高于试验对照组,可能获得更大绝对获益。

核心结论

  • 法国症状性LEAD住院患者中多数不符合低剂量利伐沙班联合阿司匹林方案,符合标准者因风险更高可能绝对获益更大。

主要发现

  • 不符合COMPASS标准的原因包括需抗凝(48.5%)、双联抗血小板(15.7%)、高出血风险(14.4%)、恶性肿瘤(26.1%)、卒中史(21.1%)、严重肾衰竭(13.2%)。
  • 不符合VOYAGER-PAD标准的原因包括需抗凝(38.9%)、双联抗血小板(16.5%)、高出血风险(11.6%)、恶性肿瘤(21.0%)、卒中史(19.8%)、严重肾衰竭(10.5%)。
  • COMPASS符合亚组主要不良心血管事件1年累积发生率6.0%(95%CI 4.3-8.1),COMPASS对照组为3.5%(95%CI 2.9-4.3)。
  • VOYAGER-PAD符合亚组主要不良肢体事件1年累积发生率27.9%(95%CI 19.9-38.3),VOYAGER-PAD对照组为6.0%(95%CI 5.3-6.9)。

关键数值与推荐

  • COMPASS符合亚组主要不良心血管事件1年累积发生率6.0%(95%CI 4.3-8.1),对照组3.5%(95%CI 2.9-4.3)。
  • VOYAGER-PAD符合亚组主要不良肢体事件1年累积发生率27.9%(95%CI 19.9-38.3),对照组6.0%(95%CI 5.3-6.9)。

临床怎么用

  • 临床中应评估症状性LEAD患者是否符合COMPASS或VOYAGER-PAD标准,符合者可能从低剂量利伐沙班联合阿司匹林治疗中获益。
  • 不符合标准者常因需抗凝、双联抗血小板、高出血风险、恶性肿瘤等,需个体化评估抗栓策略。

局限性

  • 本研究为回顾性分析,可能存在选择偏倚和信息偏倚。
  • 结果基于法国COPART注册数据,外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to examine the external applicability of the COMPASS and the VOYAGER-PAD trials in patients with lower extremity artery disease (LEAD) in the real world. METHODS: This was a multicentre retrospective analysis of prospectively collected COPART data, a French multicentre registry of patients hospitalised for symptomatic LEAD. The proportion of patients eligible for the combination of rivaroxaban 2.5 mg twice daily plus aspirin based on either COMPASS or VOYAGER-PAD criteria is reported. The one year cumulative incidence of outcomes between eligible and non-eligible patients, as well as eligible patients vs. control arms of the COMPASS (LEAD patient subgroup) and the VOYAGER-PAD trials were compared. Analyses were performed using Cox models. RESULTS: Of 2 259 evaluable patients, only 679 (30.1%) were eligible for a low dose rivaroxaban plus aspirin regimen. Others were not eligible because of the need for anticoagulant (48.5% and 38.9% of patients meeting COMPASS and VOYAGER-PAD exclusion criteria, respectively) or dual antiplatelet therapy use (15.7% and 16.5%, respectively), high bleeding risk (14.4% and 11.6%, respectively), malignancy (26.1% and 21.0%, respectively), history of ischaemic/haemorrhagic stroke (21.1% and 19.8%, respectively), and severe renal failure (13.2% and 10.5%, respectively). COMPASS and VOYAGER-PAD eligible and ineligible patients were at higher risk of ischaemic events than participants in these trials. The one year cumulative incidences were 6.0% (95% CI 4.3 - 8.1) in the COMPASS eligible subset vs. 3.5% (95% CI 2.9 - 4.3) in the COMPASS control arm for major adverse cardiovascular events, and 27.9% (95% CI 19.9 - 38.3) in the VOYAGER-PAD eligible subset vs. 6.0% (95% CI 5.3 - 6.9) in the VOYAGER-PAD control arm for major adverse limb events. CONCLUSION: Many patients hospitalised for symptomatic LEAD in France are not eligible for the low dose rivaroxaban plus aspirin combination. In turn, those eligible may potentially have greater absolute benefit because of higher risk than those enrolled in the trials.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Lapébie FX, Aboyans V, Lacroix P, et al. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry. Eur J Vasc Endovasc Surg. 2021. PMID: 34330647. doi:10.1016/j.ejvs.2021.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。